Catalyst Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced it has secured all rights to the manufacturing process for marzeptacog alfa from Wyeth LLC, a wholly-owned subsidiary of Pfizer. Marzeptacog alfa is a next-generation Factor VIIa product that was designed to allow for the effective, long-term, subcutaneous prophylaxis in hemophilia patients with inhibitors.